

Von Hippel-Lindau Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/VF3CF5189210EN.html>

Date: May 2024

Pages: 140

Price: US\$ 6,499.00 (Single User License)

ID: VF3CF5189210EN

Abstracts

The 7 major Von Hippel-Lindau disease markets are expected to exhibit a CAGR of 7.97% during 2024-2034.

The Von Hippel-Lindau disease market has been comprehensively analyzed in IMARC's new report titled "Von Hippel-Lindau Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Von Hippel-Lindau disease (VHL) refers to a rare genetic disorder that affects the growth of tumors and cysts in different parts of the body. It is caused by mutations in the VHL gene, which provides instructions for making a protein that helps to regulate cell growth and division. When this gene is mutated, it can lead to the development of abnormal growth in various organs, such as the eyes, brain, spinal cord, kidneys, pancreas, and adrenal glands. The common indications associated with this condition include headaches, hearing loss or ringing in the ears, high blood pressure, impaired balance, loss of muscle strength or coordination, vomiting, nausea, abdominal pain, vision problems, etc. Diagnosing this ailment is typically based on a review of the patient's medical history and clinical features. Genetic testing that identifies changes in chromosomes, genes, or proteins is also recommended among the population. The healthcare provider may further adopt diagnostic procedures, like magnetic resonance imaging (MRI) and computed tomography (CT) scans, to examine the affected site and confirm a diagnosis.

The increasing prevalence of hereditary conditions that produce DNA abnormalities and uncontrolled growth of harmful cells in the body is primarily driving the Von Hippel-Lindau disease market. In addition to this, the escalating application of exome sequencing tests, which can detect genetic variations associated with birth defects and

developmental delays, thereby providing an accurate diagnosis in patients, is also augmenting the market growth. Furthermore, the widespread adoption of stereotactic radiation therapy, since it delivers an adequate amount of radiation to the tumor in a shorter period of time than other traditional treatments, is creating a positive outlook for the market. Additionally, the rising demand for hypoxia-inducible factor-2 alpha inhibitor that works by declining transcription and expression of target genes related to angiogenesis, cellular proliferation, and tumor progression, is acting as another significant growth-inducing factor. Besides this, the emerging popularity of cryotherapy for treating advanced conditions, since it can fully obliterate the tumor and promote overall survival, is expected to drive the Von Hippel-Lindau disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Von Hippel-Lindau disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Von Hippel-Lindau disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Von Hippel-Lindau disease market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the Von Hippel-Lindau disease market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the Von Hippel-Lindau disease market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Von Hippel-Lindau disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug overview

Mechanism of action

Regulatory status

Clinical trial results

Drug uptake and market performance

Late-Stage Pipeline Drugs

Drug overview

Mechanism of action

Regulatory status

Clinical trial results

Drug uptake and market performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the Von Hippel-Lindau disease market performed so far and how will it perform

in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the Von Hippel-Lindau disease market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Von Hippel-Lindau disease market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Von Hippel-Lindau disease across the seven major markets?

What is the number of prevalent cases (2018-2034) of Von Hippel-Lindau disease by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of Von Hippel-Lindau disease by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with Von Hippel-Lindau disease across the seven major markets?

What is the size of the Von Hippel-Lindau disease patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of Von Hippel-Lindau disease?

What will be the growth rate of patients across the seven major markets?

Von Hippel-Lindau Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Von Hippel-Lindau disease drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the Von Hippel-Lindau disease market?

What are the key regulatory events related to the Von Hippel-Lindau disease market?

What is the structure of clinical trial landscape by status related to the Von Hippel-Lindau disease market?

What is the structure of clinical trial landscape by phase related to the Von Hippel-Lindau disease market?

What is the structure of clinical trial landscape by route of administration related to the Von Hippel-Lindau disease market?

Contents

?1 Preface

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 VON HIPPEL-LINDAU DISEASE - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 VON HIPPEL-LINDAU DISEASE - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 VON HIPPEL-LINDAU DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 VON HIPPEL-LINDAU DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 VON HIPPEL-LINDAU DISEASE - UNMET NEEDS

10 VON HIPPEL-LINDAU DISEASE - KEY ENDPOINTS OF TREATMENT

11 VON HIPPEL-LINDAU DISEASE - MARKETED PRODUCTS

- 11.1 List of Von Hippel-Lindau Disease Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Belzutifan - Peloton Therapeutics
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 VON HIPPEL-LINDAU DISEASE - PIPELINE DRUGS

12.1 List of Von Hippel-Lindau Disease Pipeline Drugs Across the Top 7 Markets

12.1.1 Drug Name - Company Name

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. VON HIPPEL-LINDAU DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. VON HIPPEL-LINDAU DISEASE – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 VON HIPPEL-LINDAU DISEASE - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Von Hippel-Lindau Disease - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Von Hippel-Lindau Disease - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Von Hippel-Lindau Disease - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Von Hippel-Lindau Disease - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

- 15.3.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Von Hippel-Lindau Disease - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Von Hippel-Lindau Disease - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Von Hippel-Lindau Disease - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Von Hippel-Lindau Disease - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Von Hippel-Lindau Disease - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Von Hippel-Lindau Disease - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Von Hippel-Lindau Disease - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Von Hippel-Lindau Disease - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Von Hippel-Lindau Disease - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Von Hippel-Lindau Disease - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)

- 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Von Hippel-Lindau Disease - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Von Hippel-Lindau Disease - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview

16 VON HIPPEL-LINDAU DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 VON HIPPEL-LINDAU DISEASE MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 VON HIPPEL-LINDAU DISEASE MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Von Hippel-Lindau Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/VF3CF5189210EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VF3CF5189210EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

